Trial · NCT04372602

Duvelisib to Combat COVID-19

NCT04372602, Phase 2, Completed, Washington University School of Medicine; results first posted 2023-03-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Duvelisib to Combat COVID-19. Trials, record NCT04372602. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04372602

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Duvelisib to Combat COVID-19
NCT number: NCT04372602
Status: Completed
Phases: Phase 2
Enrollment: 28 participants, actual
Lead sponsor: Washington University School of Medicine
Conditions: COVID-19
Interventions: Duvelisib, Peripheral blood draw, Placebo
First posted: 2020-05-04
Last updated: 2023-03-06
Results first posted: 2023-03-06

Source ClinicalTrials.gov

Registered outcomes8

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall Survival as Measured by Number of Participants Alive Through 28 Days	Through 28 days
Secondary	Length of Hospital Stay	Through 28 days
Secondary	Length of ICU Stay	Through 28 days
Secondary	Duration of Ventilator Use	Through 28 days	-For those on a ventilator at the time of randomization
Secondary	Duration of Vasopressors Use	Through 28 days
Secondary	Duration on Renal Replacement Therapy	Through 28 days
Secondary	Viral Kinetics as Measured by Virologic Failure	Through 28 days	-Defined as increase in viral load of \>0.5 log on two consecutive days, or \>1 log increase in one day, not in keeping with any baseline trend of rising viral loads during the pre-treatment viral testing
Secondary	Number of Adverse Events as Measured by CTCAE v. 5.0	Through 29 days

Source ClinicalTrials.gov

Outcomes8

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Overall Survival as Measured by Number of Participants Alive Through 28 Days	Through 28 days		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Length of Hospital Stay	Through 28 days		days	MEDIAN
SECONDARY	Length of ICU Stay	Through 28 days	1 participant was not evaluable in the placebo arm as the participant was not in the ICU.	days	MEDIAN
SECONDARY	Duration of Ventilator Use	Through 28 days	6 participants were not evaluable in the duvelisib arm as the participants were not on ventilators. 4 participants were not evaluable in the placebo arm as the participants were not on ventilators.	days	MEDIAN
SECONDARY	Duration of Vasopressors Use	Through 28 days	12 participants were not evaluable in the duvelisib arm as the participants did not receive vasopressors. 8 participants were not evaluable in the placebo arm as the participants did not receive vasopressors.	days	MEDIAN
SECONDARY	Duration on Renal Replacement Therapy	Through 28 days	14 participants were not evaluable in the duvelisib arm as the participants did not receive renal replacement therapy. 9 participants were not evaluable in the placebo arm as the participants did not receive renal replacement therapy.	days	MEDIAN
SECONDARY	Viral Kinetics as Measured by Virologic Failure	Through 28 days		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Adverse Events as Measured by CTCAE v. 5.0	Through 29 days		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group184

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Overall Survival as Measured by Number of Participants Alive Through 28 Days	Duvelisib	10		Participants
Overall Survival as Measured by Number of Participants Alive Through 28 Days	Placebo	8		Participants
Length of Hospital Stay	Duvelisib	19	Full Range 7 to 28	days
Length of Hospital Stay	Placebo	24	Full Range 7 to 28	days
Length of ICU Stay	Duvelisib	19	Full Range 5 to 28	days
Length of ICU Stay	Placebo	20.50	Full Range 7 to 28	days
Duration of Ventilator Use	Duvelisib	16	Full Range 2 to 28	days
Duration of Ventilator Use	Placebo	20	Full Range 11 to 28	days
Duration of Vasopressors Use	Duvelisib	9	Full Range 7 to 28	days
Duration of Vasopressors Use	Placebo	19	Full Range 9 to 28	days

1 to 10 of 184Source ClinicalTrials.gov

See all 184 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Duvelisib	15
Overall Study	STARTED	Placebo	13
Overall Study	COMPLETED	Duvelisib	14
Overall Study	COMPLETED	Placebo	10
Overall Study	NOT COMPLETED	Duvelisib	1
Overall Study	NOT COMPLETED	Placebo	3

Source ClinicalTrials.gov

Adverse events148

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anemia	Blood and lymphatic system disorders	Duvelisib	2	15
other	Anemia	Blood and lymphatic system disorders	Placebo	3	13
other	Leukocytosis	Blood and lymphatic system disorders	Duvelisib	0	15
other	Leukocytosis	Blood and lymphatic system disorders	Placebo	1	13
other	Atrial fibrillation	Cardiac disorders	Duvelisib	1	15
other	Atrial fibrillation	Cardiac disorders	Placebo	2	13
other	Pericarditis	Cardiac disorders	Duvelisib	1	15
other	Pericarditis	Cardiac disorders	Placebo	0	13
other	Sinus bradycardia	Cardiac disorders	Duvelisib	1	15
other	Sinus bradycardia	Cardiac disorders	Placebo	1	13

1 to 10 of 148Source ClinicalTrials.gov

See all 148 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Duvelisib	6	15
Total, all-cause mortality	Placebo	8	13
Total, other adverse events	Duvelisib	15	15
Total, other adverse events	Placebo	13	13
Total, serious adverse events	Duvelisib	6	15
Total, serious adverse events	Placebo	8	13

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
37953814	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons4

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Duvelisib vs Placebo: Viral Kinetics as Measured by Virologic Failure	Trial comparisons
Duvelisib vs Placebo: Overall Survival as Measured by Number of Participants Alive Through 28 Days	Trial comparisons
Duvelisib vs Placebo: deaths from any cause	Trial comparisons
Duvelisib vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04372602

GET https://conductscience.org/api/trials/v1/NCT04372602/results?page=2

API reference For AI assistants